Display options
Cite
Seguchi K, Nakashima K, Terao T, et al. Febrile neutropenia in a patient with non-small-cell lung cancer treated with atezolizumab: A case report. Respir Med Case Rep. 2021;33:101439doi: 10.1016/j.rmcr.2021.101439.
Seguchi, K., Nakashima, K., Terao, T., Takeshita, G., Nagai, T., & Tanaka, Y. (2021). Febrile neutropenia in a patient with non-small-cell lung cancer treated with atezolizumab: A case report. Respiratory medicine case reports, 33101439. https://doi.org/10.1016/j.rmcr.2021.101439
Seguchi, Kyosuke, et al. "Febrile neutropenia in a patient with non-small-cell lung cancer treated with atezolizumab: A case report." Respiratory medicine case reports vol. 33 (2021): 101439. doi: https://doi.org/10.1016/j.rmcr.2021.101439
Seguchi K, Nakashima K, Terao T, Takeshita G, Nagai T, Tanaka Y. Febrile neutropenia in a patient with non-small-cell lung cancer treated with atezolizumab: A case report. Respir Med Case Rep. 2021 Jun 01;33:101439. doi: 10.1016/j.rmcr.2021.101439. eCollection 2021. PMID: 34401279; PMCID: PMC8349032.
Copy Download .nbib Format: NLM
Share it on

Respir Med Case Rep. 2021 Jun 01;33:101439. doi: 10.1016/j.rmcr.2021.101439. eCollection 2021.

Febrile neutropenia in a patient with non-small-cell lung cancer treated with atezolizumab: A case report.

Respiratory medicine case reports

Kyosuke Seguchi, Kei Nakashima, Toshiki Terao, Gaku Takeshita, Tatsuya Nagai, Yu Tanaka

Affiliations

  1. Department of Pulmonology, Kameda Medical Center, Chiba, Japan.
  2. Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Chiba, Japan.

PMID: 34401279 PMCID: PMC8349032 DOI: 10.1016/j.rmcr.2021.101439

Abstract

Hematological immune-related adverse events (hem-irAEs) related to immunotherapy have not been extensively characterized, and there is no report of neutropenia caused by atezolizumab administration. Herein, we report a case of febrile neutropenia caused by a hem-irAEs due to atezolizumab, which was treated with granulocyte-colony stimulating factor (G-CSF) and antibiotic prophylaxis. It is important that oncologists be aware of the hematological toxicities of immune checkpoint inhibitors (ICIs). Furthermore, antibiotics and G-CSF should be administered until absolute neutrophil count recovery in cases of febrile neutropenia complicated by atezolizumab. Systemic corticosteroids should not be administered because they can accentuate the risk of infection.

© 2021 The Author(s).

Keywords: Atezolizumab; Hematologic immune-related adverse event; Neutropenia; Non-small-cell lung cancer

Conflict of interest statement

The authors state that they have no conflicts of interest.

References

  1. Intern Med. 2020 May 1;59(9):1199-1202 - PubMed
  2. J Clin Oncol. 2018 Jun 10;36(17):1714-1768 - PubMed
  3. Lung Cancer. 2016 Sep;99:123-6 - PubMed
  4. Immunol Lett. 2017 Mar;183:44-51 - PubMed
  5. Eur J Cancer. 2019 Nov;122:72-90 - PubMed
  6. J Clin Oncol. 2012 Jul 20;30(21):2691-7 - PubMed
  7. Lancet Haematol. 2019 Jan;6(1):e48-e57 - PubMed
  8. Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142 - PubMed
  9. N Engl J Med. 2018 Jun 14;378(24):2288-2301 - PubMed
  10. Autoimmun Rev. 2009 Sep;9(1):62-6 - PubMed
  11. N Engl J Med. 2018 Jan 11;378(2):158-168 - PubMed
  12. Blood Adv. 2017 Jul 17;1(17):1306-1308 - PubMed

Publication Types